



US006605457B1

(12) **United States Patent**
Fiers et al.

(10) **Patent No.:** **US 6,605,457 B1**
 (45) **Date of Patent:** ***Aug. 12, 2003**

(54) **INFLUENZA VACCINE**

(75) Inventors: **Walter Charles Fiers**, Destelbergen (BE); **Tom Maria Deroo**, Kurne (BE); **Willy Alfons Min Jou**, Destelbergen (BE)

(73) Assignee: **Vlaams Interuniversitair Instituut Voor Biotechnologie** (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/257,578**

(22) Filed: **Feb. 25, 1999**

Related U.S. Application Data

(63) Continuation of application No. 08/669,496, filed on Sep. 27, 1996, now Pat. No. 5,962,298.

(30) **Foreign Application Priority Data**

Jan. 11, 1994 (NL) 9400045
 Jan. 24, 1994 (EP) 94200159

(51) **Int. Cl.**⁷ **C12P 21/06**; C12N 15/09; C12N 9/00

(52) **U.S. Cl.** **435/200**; 435/69.3; 435/183; 424/186.1

(58) **Field of Search** 424/186.1; 435/69.3, 435/183, 200

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,861,864 A 8/1989 Atkinson et al. 530/324
 5,962,298 A * 10/1999 Fiers et al. 435/201

OTHER PUBLICATIONS

Mirza et al. Structure and function of a membrane anchorless form of the hemagglutinin-neuraminidase glycoprotein of newcastle disease virus. *J. Biol. Chem.*, 1993, vol. 268:21425-21431.*

Spriggs et al. Intracellular processing and transport of NH2-terminally truncated forms of hemagglutinin-neuraminidase type II glycoprotein. *J. Cell Biol.*, 1990, vol. 111(1):31-44.*

Chemical Abstracts, vol. 111, No. 1, Jul. 3, 1989, Columbus, Ohio; Abstract No. 4171q, Marina Els et al., "Sialic acid is cleaved from glyconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses." p. 403, & *Virology* vol. 170, No. 1, 1989, pp. 346-351.

Chemical Abstracts, vol. 116, No. 9, Mar. 2, 1992, Columbus, Ohio; Abstract No. 77462y, Ulrike Weyer et al., "A baculovirus dual expression vector derive from the *Autographa californica* nuclear polyhedrosis virus polyhedrin and p10 promoters: co-expression of two influenza virus genes in insect cells." p. 209, & *J. Gen Virol.*, vol. 72, No. 12, 1991, pp. 2967-2974.

Chemical Abstracts, vol. 118, No. 3, Jan. 18, 1993, Columbus, Ohio; Abstract No. 17169q, Karen Mather et al., "Expression of influenza neuraminidase in baculovirus-infected cells" p. 165; & *Virus Res.*, vol. 26, No. 2, 1992, pp. 127-139.

Chemical Abstracts, vol. 118, No. 9, Mar. 1, 1993, Columbus, Ohio; Abstract No. 77492z, Yuxin Lin et al., Expression of neuraminidase of influenza A virus in insect cells. p. 484, & *Shengwu Huaxue Yu Shengwu Wuli Xuebao*, vol. 24, No. 3, 1992, China, pp. 201-205.

Johansson et al. (1990), "Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections," *Journal of Infectious Diseases* 162:800-809.

Johansson et al. (1989), "Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection," *Journal of Virology* 63(3):1239-1246.

Paterson et al. (1990), "Conversion of a class II integral membrane protein into a soluble and efficiently secreted protein: Multiple intracellular and extracellular oligomeric and conformational forms," *J. Cell Biology* 110:999-1011.

Laver (1978), "Crystallization and peptide maps of neuraminidase "heads" from H2N2 and H3N2 influenza virus strains," *Virology* 86:78-87.

Van Rompuy et al. (1982), Complete Nucleotide Sequence of Human Influenza Neuraminidase Gene of Subtype N2 (A/Victoria/3/75), *J. Mol. Biol.* 161:1-11.

Rudinger J. (1976), "Characteristics of the amino acids as components of a peptide hormone sequence," In *Peptide Hormones*, Ed. J.A. Parsons, pp. 1-7.

Parks et al. (1990), "Folding an oligomerization properties of a soluble and secreted form of the paramyxovirus hemagglutinin-neuraminidase glycoprotein," *Virology* 178:498-508.

Castrucci et al. (1993), "Biologic importance of neuraminidase stalk length in influenza A virus," *J. Virology* 67(2):759-764.

* cited by examiner

Primary Examiner—Rebecca E. Prouty

Assistant Examiner—Manjunath N. Rao

(74) *Attorney, Agent, or Firm*—Webb Ziesenheim Logsdon Orkin & Hanson, P.C.

(57) **ABSTRACT**

A recombinant neuraminidase obtainable by culturing in a suitable culture medium host cells which are transformed with a neuraminidase expression vector or infected with a virus which is transformed with a neuraminidase expression vector, wherein the expression vector comprises at least a part of the coding region of a neuraminidase gene of an influenza virus minus the region which codes for the membrane anchor, or a modified version thereof, preceded in phase by a signal sequence; and isolating the expression product neuraminidase from the culture medium. The invention further relates to a vaccine in which the recombinant neuraminidase is applied.